Harmony Biosciences (NASDAQ:HRMY) is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders, particularly excessive daytime sleepiness and cataplexy associated with narcolepsy. The company’s activities encompass research, clinical development, regulatory submissions and commercialization efforts in the field of sleep medicine. Harmony is committed to advancing treatment options for underserved patient populations and improving long-term outcomes through targeted therapies.
The company’s flagship product, Wakix (pitolisant), is a first-in-class histamine H3 receptor antagonist/inverse agonist approved in the United States and Europe for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. Harmony is also developing HBS-102, an investigational therapy designed to address idiopathic hypersomnia, which is currently advancing through clinical trials. In addition to its own pipeline, Harmony collaborates with strategic partners to expand the reach of its therapies globally and to explore new indications.
Founded in 2018 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences emerged with a mission to fill gaps in care for patients suffering from central nervous system disorders. The company went public in March 2019, raising capital to accelerate its research and development programs. Under the leadership of President and Chief Executive Officer George Dunham, Harmony has built a specialized team of experts in neuroscience, clinical operations and regulatory affairs.
Harmony’s operations extend beyond the United States through regulatory approvals in Europe and commercial partnerships designed to bring its therapies to additional markets. The company continues to invest in clinical research, patient support programs and physician education in order to enhance awareness of rare sleep disorders and to ensure access to its treatments. Harmony’s strategic focus remains on leveraging scientific innovation to address unmet needs and improve quality of life for patients worldwide.
